Last Updated: June 28, 2026

ISOSULFAN Drug Patent Profile

Name: ISOSULFAN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Isosulfan, and what generic alternatives are available?

Isosulfan is a drug marketed by Am Regent, Eugia Pharma, Fresenius Kabi Usa, Meitheal, MSN, Mylan Institutional, Saba Ilay Sanayi, and Somerset Theraps Llc. and is included in eight NDAs.

The generic ingredient in ISOSULFAN is isosulfan blue. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the isosulfan blue profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isosulfan

A generic version of ISOSULFAN was approved as isosulfan blue by MYLAN INSTITUTIONAL on July 20^th, 2010.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ISOSULFAN?
What are the global sales for ISOSULFAN?
What is Average Wholesale Price for ISOSULFAN?

Summary for ISOSULFAN

US Patents:	0
Applicants:	8
NDAs:	8
Drug Prices:	Drug price information for ISOSULFAN
DailyMed Link:	ISOSULFAN at DailyMed

Drug patent expirations by year for ISOSULFAN

US Patents and Regulatory Information for ISOSULFAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	210294-001	May 17, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mylan Institutional	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	090874-003	Jan 28, 2026		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Meitheal	ISOSULFAN BLUE	isosulfan blue	SOLUTION;SUBCUTANEOUS	213130-001	Nov 3, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.